CTOs on the Move

Train for Compliance.

www.trainforpatientsafety.com

 
Train for Compliance. is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Milliman Care Guidelines

Milliman Care Guidelines is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hoosier

Hoosier is a Corona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RehabPath

RehabPath is a company that helps individuals find addiction and mental health treatment that fits their needs. They provide information on rehab centers, pricing, insurance, reviews, and more.

Juniper Communities

Juniper Communities was founded in 1988 and operates 18 long-term care communities in NJ, FL, PA and CO. Juniper is dedicated to Nurturing the Spirit of Life in each individual served and believes the keys to healthy aging are an active body, an engaged mind, and a fulfilled spirit. The company`s mission is to serve its stakeholders, residents, families, employee associates, and investors with excellence and strong dedication to the company`s hallmarks of quality, value and innovation.

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.